A 2-Part Study to Evaluate the Relative Bioavailability of 2 New Formulations of UCB0599 and the Effect of Esomeprazole on the PK of UCB0599 in Healthy Participants (Part A, Open-Label) and to Assess the Safety/Tolerability and PK of UCB0599 in Healthy Participants of Japanese and Chinese Origins (Part B, Double-Blind)
Latest Information Update: 06 May 2024
At a glance
- Drugs Esomeprazole (Primary) ; Minzasolmin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors UCB Biopharma
Most Recent Events
- 29 Apr 2024 Status changed from recruiting to completed.
- 14 Mar 2024 Planned primary completion date changed from 31 Mar 2024 to 1 Apr 2024.
- 08 Mar 2024 Planned End Date changed from 31 Mar 2024 to 1 Apr 2024.